Invest now
Orchid Pharma share price
High risk
You have to be logged in to add this to Watchlist.- ₹978.25(-6.58%)August 17, 2026 10:38:43 AM IST
- NSE
- BSE
- Vol : 134.96 K (NSE + BSE)Last 20 day avg : 75.99 K
Orchid Pharma is trading -6.58% lower at Rs 978.25 as compared to its last closing price. Orchid Pharma has been trading in the price range of 999.95 & 942.00. Orchid Pharma has given 37.78% in this year & 4.37% in the last 5 days. Orchid Pharma has TTM P/E ratio 122.18 as compared to the sector P/E of 32.90.There are 1 analysts who have initiated coverage on Orchid Pharma. There are 1 analysts who have given it a strong buy rating & 0.00 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 23.78 Crores in its last quarter.Listed peers of Orchid Pharma include Sun Pharmaceutical Industries (-0.57%), Divi's Laboratories (-0.08%), Torrent Pharmaceuticals (-0.14%).The Mutual Fund holding in Orchid Pharma was at 19.93% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Orchid Pharma was at 0.80% in 30 Jun 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 17 Aug 2026, 10:41 AM IST
- BetaHigh volatility1.83Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.28The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- PEG RatioIndicates undervaluation-8.13The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Orchid Pharma News
Orchid Pharma Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,914.00 | -0.57 | 4,59,221.90 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 8,493.25 | -0.08 | 2,25,469.10 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,833.40 | -0.14 | 1,83,840.43 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,432.00 | -1.24 | 1,15,684.57 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,143.10 | 0.27 | 1,14,024.67 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allOrchid Pharma Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-08-14 | Quarterly Results |
| 2026-08-01 | Allotment of Equity Shares |
| 2026-05-25 | Audited Results |
| 2026-02-11 | Quarterly Results |
| 2025-11-11 | Quarterly Results |
About the company Orchid Pharma
- IndustryBiotechnology & Drugs
- ISININE191A01027
- BSE Code524372
- NSE CodeORCHPHARMA
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of formulations and active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, and Veterinary Products. Its formulations include Cefixime Capsules, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Bio-Pharma Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc. and Diakron Pharmaceuticals, Inc.
Orchid Pharma Share Price FAQs
Orchid Pharma is trading at 978.25 as on Mon Aug 17 2026 05:08:43. This is -6.58% lower as compared to its previous closing price of 1047.10.
The market capitalization of Orchid Pharma is 4961.60 Cr as on Mon Aug 17 2026 05:08:43.
The average broker rating on Orchid Pharma is Strong Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 0.00 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Orchid Pharma is 1130.00 whereas the 52 wk low is 471.30
Orchid Pharma can be analyzed on the following key metrics -
- TTM P/E: 122.18
- Sector P/E: 32.90
- Dividend Yield: 0.00%
- D/E ratio: 0.28
Orchid Pharma reported a net profit of 20.55 Cr in 2026.
The Mutual Fund Shareholding was 19.93% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Orchid Pharma QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.